ArticleClinical rheumatology2026
Efficacy of Iguratimod-based therapy for the treatment of SAPHO syndrome: a prospective cohort study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDue to the rarity and unknown pathogenesis of SAPHO syndrome, there is no consensus on its treatment. This study aimed to evaluate the effectiveness of Iguratimod-based therapy-monotherapy or combined with alendronate-for treating SAPHO syndrome patients.
methodsWe conducted a prospective cohort study at Beijing Jishuitan Hospital from August 2022 to August 2024. Consecutively recruited patients diagnosed with SAPHO syndrome received Iguratimod monotherapy (Group A), combination therapy with Iguratimod and alendronate (Group B), or NSAIDs alone (Group C). Patients were followed for 6 months. Outcome measures included changes in Health Assessment Questionnaire (HAQ), Visual Analogue Scale (VAS), and Physician's Global Assessment of Disease Activity (PGDA) scores.
resultsSeventy-two patients (52 females, 20 males) were enrolled. Forty-seven patients completed follow-up: 19 received Iguratimod monotherapy (Group A), 26 received combination therapy (Group B), and 2 received NSAIDs monotherapy (Group C). At 6 months, both Group A and Group B showed significant reductions in HAQ, VAS, and PGDA scores compared to baseline [Group A-HAQ: 0.01 ± 0.05 vs. 0.26 ± 0.39, 95%CI(0.06, 0.43), p = 0.014; VAS: 1.42 ± 1.92 vs. 6.68 ± 1.86, 95%CI(4.16, 6.36), p < 0.001; PGDA: 1.26 ± vs. 5.74 ± 2.10, 95%CI(3.30, 5.64), p < 0.001; n = 19; Group B-HAQ: 0.01 ± 0.06 vs. 0.35 ± 0.38, 95%CI(0.18, 0.49), p < 0.001; VAS: 1.54 ± 1.65 vs. 7.04 ± 2.52, 95%CI(4.36, 6.64), p < 0.001; PGDA: 1.27 ± 1.25 vs. 5.92 ± 2.65, 95%CI(3.49, 5.82), p < 0.001; n = 26]. Significant improvements were also observed at the first month. In Group C, 66.7% (4/6) of patients required additional medications within the first month.
conclusionIguratimod-based therapy may be a potential treatment for SAPHO syndrome patients, providing rapid and sustained symptom relief over 6 months. Key Points • This is the first prospective cohort study to evaluate the efficacy of iguratimod based treatment for SAPHO syndrome. • Iguratimod may lead to rapid symptom relief for SAPHO syndrome. • The combination of iguratimod and alendronate may achieve persistent symptom improvement for SAPHO syndrome.
Indexed as
Identifiers
42247060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.